Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib

Purpose: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF receiving nintedanib can be complicated by tolerability issues, comorbidities, and concomitant medications. We developed consensus recommendations on...

Full description

Bibliographic Details
Main Authors: Franck Rahaghi, John A Belperio, John Fitzgerald, Mridu Gulati, Robert Hallowell, Kristin B Highland, Tristan J Huie, Hyun J Kim, Martin Kolb, Joseph A Lasky, Brian D Southern, Jeffrey J Swigris, Joao A de Andrade
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Online Access:https://doi.org/10.1177/11795484211006050

Internet

https://doi.org/10.1177/11795484211006050

Similar Items